Form 4: Compass Therapeutics Insider Buys Shares

Jonathan Anderman, General Counsel of Compass Therapeutics, Inc., acquired 25,000 shares of common stock.

Summary

• Jonathan Anderman, General Counsel for Compass Therapeutics, Inc., reported a transaction on April 29, 2026.
• Anderman acquired 25,000 shares of common stock at a price of $1.89 per share.
• Following this transaction, Anderman beneficially owns 196,000 shares of common stock.
• The filing also notes that 150,000 of these shares represent unvested restricted stock units (RSUs) granted on January 2, 2026, which vest in four equal annual installments, with the first installment vesting on January 2, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development due to the insider purchase, indicating confidence from a key executive, though it does not represent a significant strategic shift or financial performance update.

Positives

• Insider purchase of company stock by a key executive, which can signal confidence in the company's future prospects.
• Acquisition of 25,000 shares at a price of $1.89 per share.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this stock acquisition by a General Counsel, are closely watched by investors as they can provide insights into management's perception of the company's valuation and future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders may view this insider purchase positively, interpreting it as a sign of confidence in the company's future.

Next Steps

• Vesting of restricted stock units according to the schedule.

Key Dates

Keywords

Compass Therapeutics, CMPX, Form 4, Insider Trading, Stock Acquisition, Common Stock, Restricted Stock Units, Jonathan Anderman, General Counsel